High drug:lipid formulations of liposomal-antineoplastic agents

• US 6,083,530 A
• Filed: 05/26/1998
• Issued: 07/04/2000
• Est. Priority Date: 03/05/1987
• Status: Expired due to Term

• Current Assignee: Cephalon Ltd (Swedish Orphan Biovitrum AB (publ))
• Original Assignee: The Liposome Co., Inc. (Perrigo Company PLC)
• Inventors: Mayer, Lawrence D., Bally, Marcel B., Ginsberg, Richard S., Mitilenes, George N., Cullis, Pieter R.
• Primary Examiner(s): Lovering, Richard D.
• Application Number:
  US09/084,526
• Time in Patent Office: 770 Days
• Field of Search: 424/450, 264/4.1, 264/4.3, 428/402.2, 436/826, 436/829, 514/908
• US Class Current: 424/450
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61K 9/1278 Post-loading, e.g. by ion or pH gradient
• CPC Class Codes: Y10S 436/826 Additives, e.g. buffers, diluents, preservatives
• CPC Class Codes: Y10S 436/829 Liposomes, e.g. encapsulation
• CPC Class Codes: Y10T 428/2984 Microcapsule with fluid core [includes liposome]

Abstract

A method for encapsulation of antineoplastic agents in liposomes is provided, having preferably a high drug:lipid ratio. Liposomes may be made by a process that loads the drug by an active mechanism using a transmembrane ion gradient, preferably a transmembrane pH gradient. Using this technique, trapping efficiencies approach 100%, and liposomes may be loaded with drug immediately prior to use, eliminating stability problems related to drug retention in the liposomes. Drug:lipid ratios employed are about 3-80 fold higher than for traditional liposome preparations, and the release rate of the drug from the liposomes is reduced. An assay method to determine free antineoplastic agents in a liposome preparation is also disclosed.

Claims

1. A composition comprising:

(i) liposomes which comprise an ionizable basic antineoplastic agent, an aqueous release inhibiting buffer and a bilayer comprising a lipid; and

(ii) an aqueous solution external to the liposomes which is basic with respect to the buffer.

2. The composition of claim 1, wherein the basic antineoplastic agent is an anthracycline or a vinca alkaloid.

3. The composition of claim 2, wherein the antineoplastic agent is an anthracycline selected from the group consisting of doxorubicin and daunorubicin.

4. The composition of claim 2, wherein the antineoplastic agent is a vinca alkaloid selected from the group consisting of vincristine and vinblastine.

5. The composition of claim 4, wherein the vinca alkaloid is vincristine.

6. The composition of claim 1, wherein the lipid comprises at least one phospholipid selected from the group consisting of egg phosphatidylcholine (EPC);

distearoyl phosphatidylcholine (DSPC);

hydrogenated soy phosphatidylcholine (HSPC);

dipalmitoyl phosphatidylcholine (DPPC);

dimyristoyl phosphatidylcholine (DMPC); and

diarachidonoyl phosphatidylcholine (DAPC).

7. The composition of claim 1, wherein the liposomes are large unilamellar liposomes.

8. The composition of claim 1 comprising a pharmaceutically acceptable carrier.

9. A composition comprising:

(i) liposomes which comprise an ionizable basic antineoplastic agent, an aqueous release inhibiting buffer and a bilayer comprising a lipid;

(a) wherein the liposomes are large unilamellar liposomes;

(b) wherein the basic antineoplastic agent is an anthracycline or a vinca alkaloid;

(c) wherein the anthracycline is selected from the group consisting of doxorubicin and daunorubicin;

(d) wherein the vinca alkaloid is selected from the group consisting of vincristine and vinblastine, and wherein the preferred vinca alkaloid is vincristine;

(e) wherein the release-inhibiting buffer is a polyanionic buffer selected from the group consisting of citrate, oxalate and succinate buffers; and

(f) wherein the lipid comprises at least one phospholipid selected from the group consisting of egg phosphatidylcholine (EPC);

distearoyl phosphatidylcholine (DSPC);

hydrogenated soy phosphatidylcholine (HSPC);

dipalmitoyl phosphatidylcholine (DPPC);

dimyristoyl phosphatidylcholine (DMPC); and

diarachidonoyl phosphatidylcholine (DAPC); and

(ii) an aqueous solution external to the liposomes which is basic with respect to the buffer.

10. The composition of claim 9, wherein the release-inhibiting buffer is succinate.

11. The composition of claim 9, wherein the release-inhibiting buffer is oxalate.

12. The composition of claim 9, further comprising a pharmaceutically acceptable carrier.